1. Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil
- Author
-
Mirhelen Mendes de Abreu, Eduardo Ferreira Borba, Marcelo de Medeiros Pinheiro, Nafice Costa Araújo, Helena Lúcia Alves Pereira, Kirla Wagner Poti Gomes, Licia Maria Henrique Mota, Marcus V. G. Lacerda, Gecilmara S. Pileggi, Eduardo dos Santos Paiva, José Roberto Provenza, Camila Santana Justo Cintra Sampaio, Eloisa Bonfa, Mariana Peixoto Guimarães, Blanca Elena Rios Gomes Bica, Odirlei André Monticielo, Claudia Diniz Lopes Marques, Rafaela Cavalheiro do Espírito Santo, Thelma Larocca Skare, Ana Paula Monteiro Gomides Reis, Cleandro Pires de Albuquerque, Dante Valdetaro Bianchi, Ângela Luzia Branco Pinto Duarte, Laurindo Ferreira da Rocha Junior, Gilda Aparecida Ferreira, Vanderson Souza Sampaio, Paula Reale Fernandes, Gabriela Araújo Munhoz, Edgard Torres Reis-Neto, Evandro Mendes Klumb, Sandra Lúcia Euzébio Ribeiro, Emilia Inoue Sato, Danielle Christinne Soares Egypto de Brito, Ricardo Machado Xavier, Valeria Valim, Ana Beatriz Bacchiega, Viviane Angelina de Souza, Adriana Maria Kakehasi, and Cristina Costa Duarte Lanna
- Subjects
Adult ,Male ,medicine.medical_specialty ,Cross-sectional study ,Diseases of the musculoskeletal system ,Statistics, Nonparametric ,Arthritis, Rheumatoid ,Cohort Studies ,Young Adult ,Rheumatic diseases ,Rheumatology ,Internal medicine ,Epidemiology ,Humans ,Medicine ,Risk factor ,Aged ,Aged, 80 and over ,Family Health ,Chi-Square Distribution ,Scleroderma, Systemic ,business.industry ,Research ,COVID-19 ,Hydroxychloroquine ,RC581-607 ,Middle Aged ,medicine.disease ,Clinical trial ,Cross-Sectional Studies ,Logistic Models ,Sjogren's Syndrome ,RC925-935 ,Antirheumatic Agents ,Rheumatoid arthritis ,Hydroxycloroquine ,Female ,Immunologic diseases. Allergy ,business ,Brazil ,Cohort study ,medicine.drug - Abstract
Background There is a lack of information on the role of chronic use of hydroxychloroquine during the SARS-CoV-2 outbreak. Our aim was to compare the occurrence of COVID-19 between rheumatic disease patients on hydroxychloroquine with individuals from the same household not taking the drug during the first 8 weeks of community viral transmission in Brazil. Methods This baseline cross-sectional analysis is part of a 24-week observational multi-center study involving 22 Brazilian academic outpatient centers. All information regarding COVID-19 symptoms, epidemiological, clinical, and demographic data were recorded on a specific web-based platform using telephone calls from physicians and medical students. COVID-19 was defined according to the Brazilian Ministry of Health (BMH) criteria. Mann–Whitney, Chi-square and Exact Fisher tests were used for statistical analysis and two binary Final Logistic Regression Model by Wald test were developed using a backward-stepwise method for the presence of COVID-19. Results From March 29th to May 17st, 2020, a total of 10,443 participants were enrolled, including 5166 (53.9%) rheumatic disease patients, of whom 82.5% had systemic erythematosus lupus, 7.8% rheumatoid arthritis, 3.7% Sjögren’s syndrome and 0.8% systemic sclerosis. In total, 1822 (19.1%) participants reported flu symptoms within the 30 days prior to enrollment, of which 3.1% fulfilled the BMH criteria, but with no significant difference between rheumatic disease patients (4.03%) and controls (3.25%). After adjustments for multiple confounders, the main risk factor significantly associated with a COVID-19 diagnosis was lung disease (OR 1.63; 95% CI 1.03–2.58); and for rheumatic disease patients were diagnosis of systemic sclerosis (OR 2.8; 95% CI 1.19–6.63) and glucocorticoids above 10 mg/ day (OR 2.05; 95% CI 1.31–3.19). In addition, a recent influenza vaccination had a protective effect (OR 0.674; 95% CI 0.46–0.98). Conclusion Patients with rheumatic disease on hydroxychloroquine presented a similar occurrence of COVID-19 to household cohabitants, suggesting a lack of any protective role against SARS-CoV-2 infection. Trial registration Brazilian Registry of Clinical Trials (ReBEC; RBR – 9KTWX6).
- Published
- 2021